What did @catarina_ugc actually say?
Catarina didn't lay out a medical argument. She shared something more raw: she's taken her last dose of Mounjaro and she's upset about it. The phrase that stands out is her plea for the "food noise" and "suppression" to be nice to her now that she's off the medication. She's not claiming a cure or endorsing a protocol. She's expressing a real fear that stopping tirzepatide means the relentless mental chatter around food comes back. That's worth taking seriously, because the science actually supports her worry.
The video is emotional, not informational. But embedded in it is a legitimate clinical concern that millions of people on GLP-1 receptor agonists will eventually face: what happens when you stop?
Does the science back this up?
Yes, and more bluntly than most people want to hear. The return of food noise after stopping GLP-1 therapy is not anecdotal, it reflects what these drugs actually do mechanically. Tirzepatide (Mounjaro) works as a dual GIP and GLP-1 receptor agonist, reducing appetite partly by acting on hypothalamic circuits that regulate hunger signaling. When you remove that pharmacological input, those circuits don't stay quiet.
The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) is the clearest data point here. Participants who switched from tirzepatide to placebo after 36 weeks of treatment regained about two-thirds of their lost weight over the following 52 weeks. That rebound isn't just about calories returning, it's about hunger and food preoccupation returning. A 2023 analysis in Obesity Reviews (Wilding et al.) noted that weight regain after GLP-1 cessation mirrors the pattern seen when any energy-deficit intervention is removed, driven by compensatory increases in appetite hormones including ghrelin.
Catarina's dread is clinically well-founded. The suppression she's mourning is real, and so is its disappearance.
What did they get wrong (or right)?
She got the emotional reality right. "Food noise" is not a term invented by TikTok, it's a patient-reported outcome that researchers have started measuring formally. A 2023 paper in Diabetes, Obesity and Metabolism (Hjerpsted et al.) documented significant reductions in food cue reactivity and intrusive food thoughts during semaglutide treatment, with rebound after discontinuation. Tirzepatide data follows a similar pattern given its overlapping mechanism.
What she didn't say, and what deserves to be said clearly, is that stopping GLP-1 therapy without a plan is rarely the recommended approach. Whether she stopped due to cost, shortage, side effects, or a prescriber decision isn't clear from the video. But the framing of "I've taken my last dose" with no mention of a transition strategy is something clinicians flag. Abrupt discontinuation without behavioral support significantly worsens outcomes, according to a 2022 position statement from the Obesity Medicine Association.
There's nothing medically wrong in what she said. The concern is what she didn't say.
What should you actually know?
If you're on a GLP-1 medication and facing a stop, planned or not, the research is consistent: food noise and appetite suppression do not persist after the drug clears your system. Tirzepatide has a half-life of approximately five days, meaning meaningful receptor activity fades within two to three weeks of your last dose.
That doesn't mean you're helpless. Evidence-based behavioral interventions, specifically structured eating patterns, protein prioritization, and cognitive behavioral approaches to food cue exposure, have documented efficacy in the post-GLP-1 period, though none replicate the pharmacological appetite reduction. A 2021 trial in NEJM on liraglutide discontinuation (Rubino et al.) found that intensive behavioral counseling after stopping reduced but did not eliminate weight regain compared to placebo groups.
The honest takeaway: GLP-1 therapy currently appears to require continuation for most people to maintain its effects. That's a systemic and access problem, not a personal failure. Catarina's sadness is a real clinical signal, not just content.